thor Straten P - Search Results

1

The immunogenicity of the hTERT540-548 peptide in cancer.

Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, Andersen MH. Wenandy L, et al. Among authors: thor straten p. Clin Cancer Res. 2008 Jan 1;14(1):4-7. doi: 10.1158/1078-0432.CCR-07-4590. Clin Cancer Res. 2008. PMID: 18172245 Review.

2

Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients.

Schrama D, Andersen MH, Terheyden P, Schrøder L, Pedersen LO, thor Straten P, Becker JC. Schrama D, et al. Among authors: thor straten p. Cancer Res. 2001 Jan 15;61(2):493-6. Cancer Res. 2001. PMID: 11212239

3

In situ cytokine therapy: redistribution of clonally expanded T cells.

thor Straten P, Guldberg P, Schrama D, Andersen MH, Moerch U, Seremet T, Siedel C, Reisfeld RA, Becker JC. thor Straten P, et al. Eur J Immunol. 2001 Jan;31(1):250-8. doi: 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.0.CO;2-8. Eur J Immunol. 2001. PMID: 11265641 Free article.

4

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

Andersen MH, Pedersen LO, Capeller B, Bröcker EB, Becker JC, thor Straten P. Andersen MH, et al. Among authors: thor straten p. Cancer Res. 2001 Aug 15;61(16):5964-8. Cancer Res. 2001. PMID: 11507035

5

Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: a case report.

Pedersen LØ, Vetter CS, Mingari MC, Andersen MH, thor Straten P, Bröcker EB, Becker JC. Pedersen LØ, et al. Among authors: thor straten p. J Invest Dermatol. 2002 Apr;118(4):595-9. doi: 10.1046/j.1523-1747.2002.01698.x. J Invest Dermatol. 2002. PMID: 11918704 Free article.

6

Identification of novel survivin-derived CTL epitopes.

Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH. Reker S, et al. Among authors: thor straten p. Cancer Biol Ther. 2004 Feb;3(2):173-9. doi: 10.4161/cbt.3.2.611. Epub 2004 Feb 1. Cancer Biol Ther. 2004. PMID: 14726703

7

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P. Andersen MH, et al. Among authors: thor straten p. Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.

8

The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses.

Andersen MH, Reker S, Becker JC, thor Straten P. Andersen MH, et al. Among authors: thor straten p. J Invest Dermatol. 2004 Feb;122(2):392-9. doi: 10.1046/j.0022-202X.2004.22242.x. J Invest Dermatol. 2004. PMID: 15009721 Free article.

9

T-cell clonotypes in cancer.

Thor Straten P, Schrama D, Andersen MH, Becker JC. Thor Straten P, et al. J Transl Med. 2004 Apr 8;2(1):11. doi: 10.1186/1479-5876-2-11. J Transl Med. 2004. PMID: 15072580 Free PMC article.

10

Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients.

Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Søndergaard I, Andersen MH, Thor Straten P. Meier A, et al. Among authors: thor straten p. Cancer Immunol Immunother. 2005 Mar;54(3):219-28. doi: 10.1007/s00262-004-0578-9. Epub 2004 Oct 2. Cancer Immunol Immunother. 2005. PMID: 15580499 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

139 results

Search Page